Scope of the
Report
The report titled “Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020)” provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib.
The report titled “Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020)” provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib.
Request a sample
of this report @ http://www.orbisresearch.com/contacts/request-sample/185429 .
The report analyses the global Lynparza market in detail along with the
regional analysis as it is the only commercialized product in the market. The
clinical trials of Niraparib, Rucaparib, Talazoparib and Veliparib are also
summarized along with the anticipated market commencement for each of the
products.
The report provides detailed market potential of PARP inhibitor in
Ovarian cancer, Breast cancer, Prostate cancer and Pancreatic cancer. This
section provides the detailed analysis of the clinical trials of various PARP
inhibitors for the concerned cancer treatment.
The report also assesses the key opportunities in the market and outlines
the factors that are and will be driving the growth of the industry. Growth of
the overall global PARP inhibitor market has also been forecasted for the
period 2016-2020, taking into consideration the research & development, the
growth drivers and the current and future trends. The competition in the global
PARP inhibitor market is stiff and dominated by the big players like
AstraZeneca. Further, key players in the market, AbbVie, Clovis Oncology,
Medivation and Tesaro are also profiled with their financial information and
respective business strategies.
Purchase a copy of
Global PARP Inhibitor Market visit @ http://www.orbisresearch.com/contact/purchase/185429
For more information contact sales@orbisresearch.com .
Regional Coverage
Global
Global
Company Coverage
AstraZeneca PLC
AbbVie Inc.
Clovis Oncology, Inc.
Medivation, Inc.
Tesaro, Inc.
AstraZeneca PLC
AbbVie Inc.
Clovis Oncology, Inc.
Medivation, Inc.
Tesaro, Inc.
Executive Summary
The global PARP inhibitor market has flourished since 2015 as in late 2014, the first PARP inhibitor product was launched and projections are made that the market would rise in the next five years i.e. 2016-2020 tremendously. The market is spread across the globe with the United States and Europe dominating the market.
The global PARP inhibitor market has flourished since 2015 as in late 2014, the first PARP inhibitor product was launched and projections are made that the market would rise in the next five years i.e. 2016-2020 tremendously. The market is spread across the globe with the United States and Europe dominating the market.
The PARP inhibitor market can be segmented on the basis of the products
into Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib. Currently,
Lynparza is the only commercialized product in the market while other four
products are in the development/trial stage. The market for Veliparib is
expected to flourish since 2017 while the markets for Niraparib, Rucaparib and
Talazoparib is expected to commence from 2018.
The major growth drivers for the global PARP inhibitor market are: rise
in cancer incidences and PARP inhibitors in clinical routine. Despite the
market is governed by growth drivers, there are certain challenges faced by the
market such as: side-effects of PARP inhibitors and resistance to PARP
inhibition. Some of the recent and major trends in the market include, various
PARP inhibitors in the pipeline, inhibiting enzyme versus PARP trapping, the
combination of PARP inhibitor & c-MET and pill burden likely to decline in
the near future.
Browse Complete Report @ http://www.orbisresearch.com/reports/index/global-parp-inhibitor-market-size-trends-and-forecasts-2016-2020 .
Some points from TOC:
1. Executive Summary
2. Introduction
2.1 DNA Damage Response (DDR)
2.2 DNA Damage Response (DDR) Drug Portfolio
2.3 PARP Inhibitor
2.3.1 Introduction to PARP Inhibitor
2.3.2 Inhibiting PARP Mechanism
2.3.3 PARP Inhibitor as a Cancer Treatment
2.3.4 PARP Inhibitor Development
2.1 DNA Damage Response (DDR)
2.2 DNA Damage Response (DDR) Drug Portfolio
2.3 PARP Inhibitor
2.3.1 Introduction to PARP Inhibitor
2.3.2 Inhibiting PARP Mechanism
2.3.3 PARP Inhibitor as a Cancer Treatment
2.3.4 PARP Inhibitor Development
About Us:
Orbis Research (orbisresearch.com) is a
single point aid for all your market research requirements. We have vast
database of reports from the leading publishers and authors across the globe.
We specialize in delivering customized reports as per the requirements of our
clients. We have complete information about our publishers and hence are sure
about the accuracy of the industries and verticals of their specialization.
This helps our clients to map their needs and we produce the perfect required
market research study for our clients.
Contact
Information:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1
(214) 884-6817; +9164101019
No comments:
Post a Comment